IONpath, a US-based developer of tools to see proteins, has raised $18m in its series B round from a consortium including Bruker, a mass spectrometry company, as a new investor.
Samsara BioCapital led the B round, which included prior investors Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos IONpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund. IONpath has raised an undisclosed amount before this B round.
IONpath’s multiplexed ion beam imaging technology uses spatial proteomics at subcellular resolution down to 280 nm and so helps with spotting cancers.
Rohan Thakur, executive vice-president at Bruker, said: “The synergies… will accelerate adoption of mass spectrometry approaches for pathology.”
